Hinova Pharmaceuticals Inc
SSE:688302
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| CN |
H
|
Hinova Pharmaceuticals Inc
SSE:688302
|
4.5B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
997.2B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
578.6B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
281.8B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
303.5B USD |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
231.3B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
218.1B GBP |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.4T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
154.7B USD |
Loading...
|
|
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.6B USD |
Loading...
|
Market Distribution
| Min | -416 945.9% |
| 30th Percentile | -1.5% |
| Median | 3.5% |
| 70th Percentile | 8.9% |
| Max | 17 382.1% |
Other Profitability Ratios
Hinova Pharmaceuticals Inc
Glance View
Hinova Pharmaceuticals, Inc. engages in the research and development of pharmaceutical products. The company is headquartered in Chengdu, Sichuan and currently employs 160 full-time employees. The company went IPO on 2022-04-12. The firm focuses its research on the fields of tumor, metabolic diseases and other critical illnesses. The firm's research platforms include a deuterated drug development platform, a Proteolysis-targeting chimera (PROTAC) technology platform, a targeted drug discovery and validation platform, and a lead compound optimization screening platform. The firm has diversified product portfolios, which are in various clinical test phases, including HC-1119 for prostate cancer, HP501 for hyperuricemia, and HP558 for cancer of the esophagus, among others. The firm conducts clinical tests in domestic and overseas areas.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Hinova Pharmaceuticals Inc is -1 198.9%, which is above its 3-year median of -76 838.9%.
Over the last 3 years, Hinova Pharmaceuticals Inc’s Net Margin has increased from -18 264.8% to -1 198.9%. During this period, it reached a low of -209 088.9% on Jun 30, 2024 and a high of -1 198.9% on Jul 30, 2025.
